Prasugrel-Based De-Escalation in Patients With Acute Coronary Syndrome According to Renal Function

[1]  Samin K. Sharma,et al.  Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. , 2021, European heart journal.

[2]  J. Ware,et al.  Role of Platelets in Chronic Kidney Disease. , 2021, Journal of the American Society of Nephrology : JASN.

[3]  Catherine Martin,et al.  Adverse impact of chronic kidney disease on clinical outcomes following percutaneous coronary intervention , 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  J. Bae,et al.  Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial , 2020, The Lancet.

[5]  Deepak L. Bhatt,et al.  Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs , 2018, Thrombosis and Haemostasis.

[6]  D. Angiolillo,et al.  P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes. , 2018, Circulation.

[7]  G. Lemesle,et al.  Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease , 2018, Thrombosis and Haemostasis.

[8]  J. Spertus,et al.  Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document , 2018, Circulation.

[9]  T. Akasaka,et al.  Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO‐Kyoto Thrombotic and Bleeding Risk Scores , 2018, Journal of the American Heart Association.

[10]  J. Carrero,et al.  Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function , 2018, Heart.

[11]  P. Morange,et al.  Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study , 2017, European heart journal.

[12]  Sunil V. Rao,et al.  Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. , 2017, JACC. Cardiovascular interventions.

[13]  Yoshio Kobayashi,et al.  Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients. , 2017, Journal of cardiology.

[14]  J. Bae,et al.  Harmonizing Optimal Strategy for Treatment of coronary artery diseases – comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial , 2015, Trials.

[15]  Peter L Duffy,et al.  Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.

[16]  A. Go,et al.  Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. , 2015, Journal of the American College of Cardiology.

[17]  J. Mega,et al.  Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI , 2014, Nature Reviews Cardiology.

[18]  G. Berg,et al.  Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft‐Gault Equation , 2012, Pharmacotherapy.

[19]  P. Serruys,et al.  Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. , 2012, JACC. Cardiovascular imaging.

[20]  C. Held,et al.  Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2011, European heart journal.

[21]  M. Flather,et al.  Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. , 2011, Journal of the American Society of Nephrology : JASN.

[22]  C. Stehouwer,et al.  Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study. , 2008, Clinical nephrology.

[23]  E. Antman,et al.  Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. , 2008, Journal of the American College of Cardiology.

[24]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[25]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[26]  M. Pencina,et al.  In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. , 2009, JACC. Cardiovascular interventions.